- 2019
-
Press releases - 17.04.2019
The overall annual cost of infections due to bacterial resistance in French hospitals now estimated up to 290 million Euros
Une équipe de chercheurs est parvenue à estimer le nombre de nouveaux cas et le coût économique direct que représentent les infections à bactéries résistantes aux antibiotiques chez les malades hospitalisés, pendant les années 2015 et 2016.
-
Press releases - 12.04.2019
Hypertension: A New Drug Coming Soon?
Firibastat is the first in a new class of antihypertensive drugs targeting the renin-angiotensin system in the brain.
-
Press releases - 10.04.2019
ChroMS – the brain as never seen before
ChroMS is a new microscopy technique bringing together color, 3D and high-resolution imaging, and is nothing short of a revolution in vertebrate brain imaging.
-
Press releases - 08.04.2019
Flu Shot: Cutaneous Administration Improves Efficacy
The team of Béhazine Combadière, Inserm Research Director at Unit 1135 “Center for Immunology and Infectious Diseases”, has been working for years on the impact of vaccine administration routes on the quality of immune responses.
-
Press releases - 05.04.2019
Cesarean Delivery Linked to Increased Risk of Severe Maternal Complications
Cesarean delivery is thought to be linked to a greater risk of severe maternal complications – primarily hemorrhagic – than vaginal delivery, especially in women aged 35 and over.
-
Press releases - 02.04.2019
Narcolepsy: A New Drug to Fight Sleepiness
How can the quality of life of patients with narcolepsy, the severest sleep disorder in humans, be improved? An international scientific team led by Yves Dauvilliers, a researcher at Inserm and Université de Montpellier, is working on Solriamfetol – a promising new drug that stimulates alertness and improves resistance to sleepiness.
-
Press releases - 27.03.2019
Nanoblades: shuttles for genome surgery
Researchers are now able to edit the genome with precision using the “gene editing scissors” of CRISPR-Cas9, which is a highly promising tool for gene therapy. The technical challenge now is to get this tool into the genome of certain cells. With this in mind, a joint team from Inserm, the CNRS, the Université Claude Bernard Lyon 1, and the École Normale Supérieure de Lyon, working within the International Center for Infectiology Research (CIRI), have developed capsules that allow CRISPR-Cas9 to reach the target DNA: Nanoblades.
-
Press releases - 26.03.2019
HIV/tuberculosis co-infection: tunnelling towards better diagnosis
1.2 million people in the world are co-infected by Mycobacterium tuberculosis, the bacteria which causes tuberculosis, and AIDS (HIV-1). This combination is deadly: it makes patient diagnosis and treatment difficult, and increases the pathogenicity of these two infectious agents. An international team led by researchers at the CNRS and Inserm have revealed that in the presence of tuberculosis, HIV-1 moves from one cell to the next via nanotubes which form between macrophages, drastically increasing the percentage of infected cells. These findings appear in the 26 March 2019 edition of Cell Reports.
-
Press releases - 25.03.2019
A Gene Therapy Tested in the Treatment of Myotubular Myopathy
Inserm and CNRS researchers from the Institute of Genetics and Molecular and Cellular Biology (Inserm/CNRS/Université de Strasbourg) have discovered how myotubularin – a protein deficient in myotubular myopathy – interacts with amphiphysin 2 and suggest targeting the latter in order to treat patients.
-
Press releases - 19.03.2019
Découverte d’une réaction immunitaire cruciale lors de la diversification alimentaire pour prévenir l’apparition des maladies inflammatoires
Les microbes colonisent l’ensemble des surfaces de notre corps et participent au bon équilibre de notre système immunitaire. Chez les nouveau-nés, le microbiote intestinal est d’abord formaté par les composants du lait maternel. Lors de la diversification alimentaire, il se développe et de nombreuses bactéries prolifèrent. Des chercheurs de l’Institut Pasteur et de l’Inserm montrent chez la souris qu’une réponse immunitaire importante se produit lors de l’introduction de nourriture solide et du développement du microbiote. Mais surtout, ils ont montré que cette réaction immunitaire était essentielle car elle participe à l’éducation du système immunitaire, et permet, à l’âge adulte, une faible susceptibilité aux maladies inflammatoires (allergies, colites, maladies auto-immunes, cancer). Ces résultats ont été publiés dans la revue Immunity, le 19 mars 2019.